AIM ImmunoTech Inc. — Director's Dealing 2016

Dec 23, 2016

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: HEMISPHERX BIOPHARMA INC (HEB)
CIK: 0000946644
Period of Report: 2016-12-22

Reporting Person: Equels Thomas K. (Director, CEO, President)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2016-12-22	Common Stock	P	68493	$0.73	Acquired	220455	Direct